3Bosch J, Abraldes JG, Berzigotti A, et al. Portal hyper- tension and gastrointestinal bleeding[J]. Semin Liver Dis, 2008, 28(1): 3-25.
4Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in pa- tients with HCV-related cirrhosis[J]. Hepatology, 2007, 45(5): 1290-1297.
5Kazemi F, Kettaneh A, N'kontchou G, et al. Liver stiff- ness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices[J]. J Hepatol, 2006, 45(2): 230-235.
6Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta- blockers to prevent gastroesophageal varices in patientswith cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254- 2261.
7Stanley A J, Therapondos G, Helmy A, et al. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis[J]. J Hepatol, 1999, 30(3): 479- 484.
8Bafiares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alphal- adrenergie activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis[J]. Hepatology, 1999, 30(1): 79-83.
9Bafiares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol ad- ministration in the treatment of portal hypertension in cir- rhosis[J]. Hepatology, 2002, 36(6): 1367-1373.
10Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic pa- tients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11): 1634-1641.
